Index RUT P/E - EPS (ttm) - Insider Own 30.41% Shs Outstand 14.48M Perf Week -4.90%
Market Cap 213.72M Forward P/E - EPS next Y - Insider Trans 0.46% Shs Float 10.07M Perf Month -7.98%
Income - PEG - EPS next Q -3.38 Inst Own 63.74% Short Float 6.73% Perf Quarter 8.45%
Sales - P/S - EPS this Y - Inst Trans 32.31% Short Ratio 6.12 Perf Half Y -
Book/sh 15.15 P/B 0.97 EPS next Y - ROA - Short Interest 0.68M Perf Year -
Cash/sh 15.67 P/C 0.94 EPS next 5Y - ROE - 52W Range 10.80 - 18.95 Perf YTD 6.03%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -22.11% Beta -
Dividend TTM - Quick Ratio 6.20 Sales past 5Y -17.88% Gross Margin - 52W Low 36.67% ATR (14) 0.72
Dividend Ex-Date - Current Ratio 6.20 EPS Y/Y TTM - Oper. Margin - RSI (14) 44.41 Volatility 3.40% 4.77%
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.33 Target Price 24.00
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 0.48 Prev Close 14.88
Sales Surprise - EPS Surprise 3585.56% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 110.81K Price 14.76
SMA20 -6.63% SMA50 3.07% SMA200 1.83% Trades
Volume 53,308 Change -0.81%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-23-24 Initiated JMP Securities
Mkt Perform
Sep-13-24 01:55AM
Aug-13-24 06:54PM
May-24-24 04:00PM
May-10-24 06:36PM
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded on January 8, 2024 and is headquartered in La Jolla, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lappe Mark Chief Executive Officer Sep 12 '24 Buy 15.05 26,963 405,793 692,511 Sep 16 05:12 PM Lappe Mark Chief Executive Officer Sep 16 '24 Buy 17.13 13,037 223,324 705,548 Sep 16 05:12 PM Vuori Kristiina MD Director Sep 11 '24 Buy 15.07 6,457 97,307 13,776 Sep 12 05:14 PM Vuori Kristiina MD Director Sep 10 '24 Buy 15.00 179 2,685 7,319 Sep 12 05:14 PM Lappe Mark Chief Executive Officer Sep 06 '24 Buy 15.29 26,000 397,540 647,548 Sep 10 05:00 PM Lappe Mark Chief Executive Officer Sep 09 '24 Buy 15.21 9,500 144,495 657,048 Sep 10 05:00 PM Lappe Mark Chief Executive Officer Sep 10 '24 Buy 15.19 8,500 129,115 665,548 Sep 10 05:00 PM Lappe Mark Chief Executive Officer Sep 03 '24 Buy 15.81 20,000 316,263 165,000 Sep 03 05:31 PM Lappe Mark Chief Executive Officer Aug 29 '24 Buy 14.03 10,000 140,300 135,000 Sep 03 05:31 PM Lappe Mark Chief Executive Officer Aug 30 '24 Buy 14.02 10,000 140,200 145,000 Sep 03 05:31 PM Vuori Kristiina MD Director Aug 29 '24 Buy 14.00 7,140 99,960 7,140 Sep 03 04:27 PM MANHARD KIMBERLY Director Aug 28 '24 Buy 13.98 10,000 139,800 10,000 Aug 30 04:16 PM FORSYTH DOUGLAS Director Aug 23 '24 Buy 14.07 59,812 841,555 224,564 Aug 26 04:26 PM FORSYTH DOUGLAS Director Aug 22 '24 Buy 12.89 15,188 195,773 164,752 Aug 26 04:26 PM Lappe Mark Chief Executive Officer Aug 20 '24 Buy 12.97 27,055 350,903 41,920 Aug 22 04:29 PM Lappe Mark Chief Executive Officer Aug 21 '24 Buy 12.93 12,945 167,379 54,865 Aug 22 04:29 PM Kayyem Jon Faiz Director Jun 05 '24 Buy 17.32 57,549 997,024 1,150,410 Jun 07 06:05 PM Eckelman Brendan P. Chief Scientific Officer May 28 '24 Sale 34.30 300,000 10,290,000 1,735,553 May 30 06:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
